ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
WuXi Biologics is expanding its capacity with two acquisitions. The biologic drug contract manufacturer will buy Pfizer’s plant in Hangzhou, China, which features two 2,000 L single-use bioreactors plus finished-drug capabilities. And WuXi will purchase most of CMAB Biopharma, a contract biologics firm in Suzhou, China, with 7,000 L of bioreactor capacity plus the facilities for producing finished drugs.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter